| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | 4.0 | -4.9 |
| EPS (diluted, $ a share) | $0.00 | $-9.10 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, OTC: CERO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Cero Therapeutics Holdings, Inc.: key numbers
- Share price
- $0.0041Close, Nov 17
- Market cap
- $337K
- Shares outstanding
- 83.31MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Cero Therapeutics Holdings, Inc.
All →Cero Therapeutics Holdings Divestiture to SRX Global Inc. for $10.8M
CERo Therapeutics Holdings, Inc. entered into a definitive agreement to sell its wholly owned operating subsidiary, CERo Therapeutics, Inc., to SRX Global Inc. The consideration includes $1 million in SRX common stock, the assumption of approximately $1.562 million in liabilities, and the forgiveness of a senior secured promissory note with an outstanding balance of approximately $8.25 million. The agreement includes a 30-day 'go-shop' period allowing the company to solicit superior proposals.
- Value
- $10.8M
- Counterparty
- SRX Global Inc.